Country |
Not used in the past month/occasional |
Once a week or less |
2 - 6 times per week |
Daily |
Base |
Status unknown |
|---|---|---|---|---|---|---|
Czech Republic |
27.4 |
29.6 |
31.1 |
11.9 |
328 |
18 |
Denmark |
0.0 |
32.8 |
50.4 |
16.8 |
125 |
52 |
Germany |
74.0 |
13.1 |
9.6 |
3.3 |
6753 |
0 |
Greece |
66.7 |
16.7 |
16.7 |
0.0 |
6 |
0 |
Cyprus |
12.5 |
25.0 |
50.0 |
12.5 |
8 |
0 |
Latvia |
0.0 |
6.3 |
25.0 |
68.8 |
16 |
4 |
Malta |
50.0 |
50.0 |
0.0 |
0.0 |
2 |
1 |
Netherlands |
23.9 |
12.4 |
24.8 |
38.8 |
322 |
34 |
Slovenia |
0.0 |
80.0 |
20.0 |
0.0 |
5 |
0 |
Slovakia |
5.7 |
32.4 |
40.0 |
21.9 |
105 |
21 |
Finland |
23.8 |
20.1 |
44.5 |
11.6 |
164 |
0 |
Sweden |
20.7 |
23.7 |
40.0 |
15.6 |
135 |
9 |
Bulgaria |
25.0 |
25.0 |
25.0 |
25.0 |
4 |
0 |
Total |
65.8 |
14.7 |
13.4 |
6.1 |
7973 |
139 |
Notes: Only countries where there are clients reported with stimulants as primary drug are shown. Source: 2004 Reitox national reports - TDI - outpatient treatment centres – see [Table TDI-17] | ||||||